Logo image
Antifungal Activity of Tamoxifen: In Vitro and In Vivo Activities and Mechanistic Characterization
Journal article   Open access   Peer reviewed

Antifungal Activity of Tamoxifen: In Vitro and In Vivo Activities and Mechanistic Characterization

Kristy Dolan, Sara Montgomery, Bradley Buchheit, Louis DiDone, Melanie Wellington and Damian J Krysan
Antimicrobial agents and chemotherapy, Vol.53(8), pp.3337-3346
08/2009
DOI: 10.1128/AAC.01564-08
PMCID: PMC2715577
PMID: 19487443
url
https://doi.org/10.1128/AAC.01564-08View
Published (Version of record) Open Access

Abstract

Tamoxifen (TAM), an estrogen receptor antagonist used primarily to treat breast cancer, has well-recognized antifungal properties, but the activity of TAM has not been fully characterized using standardized (i.e., CLSI) in vitro susceptibility testing, nor has it been demonstrated in an in vivo model of fungal infection. In addition, its mechanism of action remains to be clearly defined at the molecular level. Here, we report that TAM displays in vitro activity (MIC, 8 to 64 μg/ml) against pathogenic yeasts ( Candida albicans , other Candida spp., and Cryptococcus neoformans ). In vivo, 200 mg/kg of body weight per day TAM reduced kidney fungal burden (−1.5 log 10 CFU per g tissue; P = 0.008) in a murine model of disseminated candidiasis. TAM is a known inhibitor of mammalian calmodulin, and TAM-treated yeast show phenotypes consistent with decreased calmodulin function, including lysis, decreased new bud formation, disrupted actin polarization, and decreased germ tube formation. The overexpression of calmodulin suppresses TAM toxicity, hypofunctional calmodulin mutants are hypersensitive to TAM, and TAM interferes with the interaction between Myo2p and calmodulin, suggesting that TAM targets calmodulin as part of its mechanism of action. Taken together, these experiments indicate that the further study of compounds related to TAM as antifungal agents is warranted.
Mechanisms of Action Physiological Effects

Details

Metrics

Logo image